| pubmed-article:11870722 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11870722 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11870722 | lifeskim:mentions | umls-concept:C0028778 | lld:lifeskim |
| pubmed-article:11870722 | lifeskim:mentions | umls-concept:C0034830 | lld:lifeskim |
| pubmed-article:11870722 | lifeskim:mentions | umls-concept:C0020852 | lld:lifeskim |
| pubmed-article:11870722 | lifeskim:mentions | umls-concept:C0439799 | lld:lifeskim |
| pubmed-article:11870722 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11870722 | pubmed:dateCreated | 2002-2-28 | lld:pubmed |
| pubmed-article:11870722 | pubmed:abstractText | In myasthenia gravis (MG), specific antibodies directed against nicotinic acetylcholine receptor (nAChR) channels are produced. Recently, a distinct blockade of native embryonic-type nAChR channels by purified IgG from MG patients has been demonstrated. In the present study, we investigated the interaction of myasthenic IgG with recombinant embryonic- or adult-type nAChR channels expressed on human embryonic kidney (HEK) 293 cells. For the experiments, the patch clamp technique was applied in combination with an ultra-fast application system for agonists. Repetitive 20-ms pulses of 1 mM acetylcholine (ACh) were applied with or without purified IgG added to the perfusion system. The purified IgG from MG patients blocked currents through both, embryonic- and adult-type nAChR channels to a similar extent. A block by myasthenic IgG of adult-type nAChR channels, which are present exclusively at the postsynaptic membrane of the neuromuscular synapse, was shown to occur. The reversible pharmacological blockade of adult-type nAChR channels by myasthenic IgG may be one factor responsible for rapid fluctuations of weakness or rapid recovery of muscle strength after plasmapheresis in MG. | lld:pubmed |
| pubmed-article:11870722 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11870722 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870722 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11870722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870722 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11870722 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11870722 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:11870722 | pubmed:issn | 0148-639X | lld:pubmed |
| pubmed-article:11870722 | pubmed:author | pubmed-author:DenglerReinha... | lld:pubmed |
| pubmed-article:11870722 | pubmed:author | pubmed-author:KrampflKlausK | lld:pubmed |
| pubmed-article:11870722 | pubmed:author | pubmed-author:BuflerJohanne... | lld:pubmed |
| pubmed-article:11870722 | pubmed:copyrightInfo | Copyright 2002 Wiley Periodicals, Inc. | lld:pubmed |
| pubmed-article:11870722 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11870722 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:11870722 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11870722 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11870722 | pubmed:pagination | 433-7 | lld:pubmed |
| pubmed-article:11870722 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:meshHeading | pubmed-meshheading:11870722... | lld:pubmed |
| pubmed-article:11870722 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11870722 | pubmed:articleTitle | Block of recombinant nicotinic receptor channels by IgG from myasthenic patients. | lld:pubmed |
| pubmed-article:11870722 | pubmed:affiliation | Department of Neurology, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. | lld:pubmed |
| pubmed-article:11870722 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11870722 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
